Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767638 | 0.91 | BCHE (0.34) | BCHEACHE | |
| SCHEMBL767690 | 0.85 | TDP1 (0.37) | TDP1LMNAPOLBALDH1A1CYP1A2 | |
| SCHEMBL767562 | 0.80 | L3MBTL1 (0.35) | TDP1HSD17B10POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL767768 | 0.79 | TDP1 (0.38) | TDP1BCHEACHEALDH1A1 | |
| SCHEMBL767693 | 0.79 | PRMT5 (0.32) | TDP1BCHEACHE | |
| SCHEMBL767666 | 0.77 | SYK (0.35) | TDP1LMNAMAPK1POLBALDH1A1 | |
| SCHEMBL767624 | 0.76 | L3MBTL1 (0.42) | LMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL767688 | 0.76 | SYK (0.34) | TDP1LMNAMAPK1POLBALDH1A1 | |
| SCHEMBL767511 | 0.76 | KDM1A (0.31) | — | |
| SCHEMBL767748 | 0.73 | GAA (0.32) | TDP1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | TDP1 603/4885HSD17B10 3174/4885LMNA 839/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | TDP1 615/4885HSD17B10 3160/4885LMNA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.